Introduction
============

As one of the most fatal types of human malignant cancer, pancreatic ductal adenocarcinoma (PDAC) exhibits a poor prognosis, despite significant advances in diagnostic and therapeutic options, and has the lowest 5 year relative survival rate of 6% reported in 2016 in North America ([@b1-ol-0-0-10809],[@b2-ol-0-0-10809]). Difficulties in detecting the disease at an early stage partially contribute to the poor prognosis ([@b3-ol-0-0-10809]). The search for novel biomarkers to detect and diagnose PDAC has been of interest to clinicians and researchers. Carbohydrate antigen 19-9 (CA19-9), the only authenticated marker for clinical application, lacks the specificity required for a differential diagnosis ([@b4-ol-0-0-10809],[@b5-ol-0-0-10809]). The majority of other markers are expensive or experimental, and are not widely used in routine clinical practice ([@b6-ol-0-0-10809],[@b7-ol-0-0-10809]). Therefore, there is an urgent need to identify convenient and easily applicable biomarkers for PDAC.

Peripheral blood examination is one of the most frequently used measures in tumor management. However, it is relatively rare to regard variables excluded from routine blood count parameters as prognostic factors ([@b8-ol-0-0-10809]). The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) at the initial diagnosis may serve as simple indexes of immune function, and each one is reported to be a prognostic factor in a number of different types of malignant tumor, such as Hodgkin\'s lymphoma, and bladder and hepatocellular cancer ([@b9-ol-0-0-10809]--[@b12-ol-0-0-10809]). However, their prognostic significance is controversial for patients with pancreatic cancer. Martin *et al* ([@b13-ol-0-0-10809]) investigated the effects of systemic inflammation-based factors, including NLR and PLR, on the outcome of patients with tumors, and concluded that both NLR and PLR were independent prognostic markers. However, Aliustaoglu *et al* ([@b14-ol-0-0-10809]) proposed that NLR was a superior marker for patients with pancreatic cancer. Furthermore, a previous study investigated the association between LMR and PDAC; one study indicated that low LMR predicted a poor prognosis in patients with resectable PDAC, but no further studies were pursued ([@b15-ol-0-0-10809]). Therefore, the prognostic value of the peripheral blood NLR, PLR and LMR in patients with PDAC was examined in the present study.

S100 calcium-binding protein A4 (S100A4), a member of the S100 family of calcium-binding proteins, promotes tumor metastasis, proliferation and immune evasion ([@b16-ol-0-0-10809]--[@b19-ol-0-0-10809]). A previous study has verified the hypothesis that S100A4-mediated metastasis is associated with extensive T-cell infiltration or tumor-associated neutrophils ([@b20-ol-0-0-10809]). S100A4 tissue expression was associated with a poor prognostic outcome in a variety of cancer types, including PDAC, and lung and breast cancer ([@b21-ol-0-0-10809],[@b22-ol-0-0-10809]). In the present study, the association between the pre-treatment peripheral blood NLR, PLR or LMR and S100A4 tissue expression was analyzed in 258 patients diagnosed with PDAC.

Materials and methods
=====================

### Patient eligibility

The present study was conducted at the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China). The study was approved by the Ethics Committee and all patients provided written informed consent. Patients with PDAC hospitalized between December 2008 and December 2014 were enrolled in the study. The clinical records of these patients were reviewed retrospectively. The inclusion criteria were: i) Patients were hospitalized for primary diagnosis and had received no treatment prior to diagnosis (therapy naïve); ii) patients were histologically diagnosed with primary PDAC and staged according to the Tumor-Node-Metastasis (TNM) criteria of the American Joint Committee on Cancer, 2017 ([@b23-ol-0-0-10809]); and iii) all clinical data for the patients were available. The exclusion criteria were: i) Patients did not have primary PDAC; ii) the detailed and required clinical data were unavailable; iii) patients had prior clinical evidence of infection, other inflammation, pulmonary embolism, acute myocardial infarction, cerebrovascular accident or hematological disease, or were taking drugs for hematological disorders; iv) patients had received prior radiation therapy, chemotherapy or surgery; and v) contact with the patients was lost during the follow-up time.

### Clinical and laboratory data collection

Data regarding the patients, the tumor characteristics, the diagnosis and the treatment modalities were collected and retrospectively reviewed. In the current study, the majority of the complications were anastomotic leakage and ischemia-reperfusion; drug-controlled complications such as fever or abdominal infection were not included. For all study subjects, blood samples were collected at the first consultation in edathamil-2K preservative tubes, stored at room temperature and analyzed using the same hematology analyzer within 48 h; differential leukocyte counts were recorded. The NLR, PLR and LMR were defined as the absolute neutrophil count divided by the absolute lymphocyte count, the absolute platelet count divided by the absolute lymphocyte count and the absolute lymphocyte count divided by the absolute monocyte count, respectively, in the laboratory tests prior to treatment. Tumor tissues and adjacent healthy tissues were collected during surgery or by 18-G needle biopsy.

### Histopathological analysis

Tissues were fixed with 4% formalin at room temperature within 48 h, embedded in paraffin, and diagnosed clinically and histopathologically at the Departments of Pancreatic Cancer and Pathology. All pathological data were analyzed by two pathologists independently.

Immunohistochemical (IHC) analysis was performed to evaluate the expression levels of S100A4 as previously described ([@b24-ol-0-0-10809]). Briefly, tissue sections with thickness of 3 µm were incubated at 60°C for 2 h followed by deparaffinization with xylene and rehydration in concentrations of 100, 95, 85 and 75% alcohol, respectively. The sections were submerged in ethylenediamine tetraacetic acid antigen retrieval buffer (Beijing Solarbio Science & Technology Co., Ltd.) and heated in a microwave for 2 min for antigen retrieval, treated with 3% hydrogen peroxide at room temperature for 10 min in methanol to quench endogenous peroxidase activity and incubated with 1% bovine serum albumin (Amresco LLC) to block non-specific binding. The sections were incubated with mouse anti-S100A4 (1:2,000; cat. no. ab197896; Abcam,) and diluent (cat. no. ZLI-9030; Origene Technologies, Inc.) overnight at 4°C. Normal goat serum (Origene Technologies, Inc.) was used as a negative control. Tissues were subsequently incubated with the secondary antibody (cat. no. K183316C; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.) at 37°C for 1 h. Following 3 PBS washes, the tissue sections were counterstained with hematoxylin at room temperature for 3 min, dehydrated and mounted.

The degree of IHC staining was reviewed and scored independently by two pathologists. IHC was scored by multiplying the scores of the percentage of positive tumor cells and staining intensity. The percentage of positive tumor cells was scored as 0 (0%), 1 (1--25%), 2 (26--50%), 3 (51--75%) or 4 (76--100%). Staining intensity was scored as 0 (negative), 1 (weakly positive), 2 (moderately positive) or 3 (strongly positive). According to the staining results, the S100A4 tissue expression level was classified into two groups: Negative (score \<3) and positive (score ≥3).

### Statistical analysis

Follow-up time was defined as the time between admission and August 2015. Overall survival (OS) time was defined as the interval between the time of diagnosis and final follow-up or death. Statistical analyses were performed using SPSS software version 21.0 (IBM Corp.). A χ^2^ test was performed to compare baseline clinical characteristics between patients of different subgroups. The survival curves were produced using Kaplan-Meier analysis. The log-rank and multivariate Cox proportional hazards regression model analyses were performed to determine the independent prognostic factors and survival function. The mean NLR, PLR and LMR data was compared for the subgroups with positive and negative S100A4 expression using an unpaired Student\'s t-test. X-tile analysis was used to identify the best cut-off value for low and high NLR, PLR and LMR. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

Among the 258 patients with PDAC, the mean age was 59 years (median, 58.64 years; range, 21--75 years). The median OS time was 9 months (range, 1--32 months). A total of 105 patients were diagnosed based on the results of a biopsy, 70 patients received palliative surgery and 83 received radical surgery. Adjuvant chemotherapy and radiation therapy were performed following the biopsy or surgery. The median CA19-9 level was 260.45 U/ml (range, 0--100,254 U/ml). The clinicopathological characteristics of the patients and treatment modalities are presented in [Table I](#tI-ol-0-0-10809){ref-type="table"}.

### Patient peripheral blood characteristics

At diagnosis, the median NLR, PLR and LMR were 2.55 (range, 0.63--19.00), 142.09 (range, 16.49--1,316.67) and 3.13 (range, 0.30--42.33), respectively. The baseline characteristics of the patients grouped by NLR, PLR or LMR quartiles are presented in [Tables II](#tII-ol-0-0-10809){ref-type="table"}--[IV](#tIV-ol-0-0-10809){ref-type="table"}. The skewed frequency distribution of NLR, PLR and LMR is presented in [Fig. 1](#f1-ol-0-0-10809){ref-type="fig"}, the majority of the patients exhibited NLR\<5, PLR\<250 and LMR\<10.

Patients in the highest NLR quartile were primarily male and had more pancreatic tumors of head and neck origin compared with the lowest quartile. In addition, the CA19-9 value was higher compared with that in the lowest NLR quartile ([Table II](#tII-ol-0-0-10809){ref-type="table"}). The patients in the highest PLR quartile had more pancreatic tumors of head and neck origin compared with those in the lowest PLR quartile. In addition, patients in the highest quartile were less likely to receive radiotherapy ([Table III](#tIII-ol-0-0-10809){ref-type="table"}). The patients in the highest LMR quartile were primarily female compared with those in the lowest LMR quartile and no significant differences existed in the characteristics of the patients between the two groups ([Table IV](#tIV-ol-0-0-10809){ref-type="table"}).

A significant increase was observed in OS among the patients in the lowest NLR quartile compared with those in the highest NLR quartile (median survival rate, 50.7 vs. 31.3%, respectively; P\<0.05; [Fig. 2A](#f2-ol-0-0-10809){ref-type="fig"}). No statistically significant difference was observed in the OS between patients in the lowest PRL quartile and those in the highest quartile (49.5 vs. 38.1%, respectively; P\>0.05; [Fig. 2B](#f2-ol-0-0-10809){ref-type="fig"}). By contrast, there was a significant decrease in OS between patients in the lowest LMR quartile compared with those with in the highest LMR quartile (28.3 vs. 57.8%; P\<0.05; [Fig. 2C](#f2-ol-0-0-10809){ref-type="fig"}).

### Risk factors of mortality

According to the univariate analysis, higher NLR, age, CA19-9 level, stage and histological grade were associated with a higher risk of mortality, whereas surgery, chemotherapy and higher LMR were associated with lower mortality ([Table V](#tV-ol-0-0-10809){ref-type="table"}). The univariate analysis revealed that PLR had no significant effect on OS. The hazard ratio of mortality of patients with PDAC in the highest NLR quartile increased 1.765-fold (P=0.007) compared with those in the lowest. However, the hazard ratio of mortality of patients with PDAC in the highest LMR quartile decreased 0.501-fold (P=0.001) compared with those in the lowest LMR quartile ([Table V](#tV-ol-0-0-10809){ref-type="table"}).

### Role of NLR, PLR and LMR as an independent predictor of mortality in PDAC

The variables associated with NLR quartile and survival status in the Cox regression analyses were included in the Cox proportional hazard multivariate model, and all variables included in [Table VI](#tVI-ol-0-0-10809){ref-type="table"} were associated with NLR quartile in previous analyses. The Cox proportional hazard multivariate analysis was performed separately to avoid combining NLR, PLR and LMR into one model, as they were highly associated with absolute lymphocyte counts. The results revealed that NLR was an independent predictor of mortality with a hazard ratio of 1.198 (P=0.017) as a continuous variable, whereas 1.543 as a categorical variable (P=0.058), therefore NLR cannot be used as an independent predictor of mortality as a categorical variable. As a continuous variable, LMR was an independent predictor of mortality with a hazard ratio of 0.846 (P=0.021), but it was not a predictor as a categorical variable (hazard ratio, 0.663; P=0.074). PLR was not an independent predictor as a continuous or categorical variable ([Table VI](#tVI-ol-0-0-10809){ref-type="table"}).

### S100A4 expression and its association with peripheral blood NLR, PLR and LMR

The levels of peripheral blood NLR, PLR and LMR were analyzed in the subgroups of different expression levels of S100A4 ([Fig. 3A](#f3-ol-0-0-10809){ref-type="fig"}). The number of patients with negative and positive tissue expression levels of S100A4 was 60 and 198, respectively. High expression levels of S100A4 were demonstrated to be associated with worse OS (P=0.003; [Fig. 3B](#f3-ol-0-0-10809){ref-type="fig"}). The median value of NLR, PLR and LMR in the subgroup of negative S100A4 expression was 1.50, 114.19 and 4.70, respectively ([Fig. 4](#f4-ol-0-0-10809){ref-type="fig"}). The mean value of NLR, PLR and LMR in the subgroup of positive S100A4 expression was 3.93 (median, 3.16), 181.10 (median, 152.45) and 3.46 (median, 2.73), respectively ([Fig. 4](#f4-ol-0-0-10809){ref-type="fig"}). The levels of NLR and PLR in patients with positive S100A4 expression were higher compared with those in the negative S100A4 expression group (P\<0.001 and P=0.001, respectively), whereas the level of LMR in patients with positive S100A4 expression was lower compared with that in the negative S100A4 expression group (P=0.001; [Fig. 4](#f4-ol-0-0-10809){ref-type="fig"}).

Kaplan Meier survival analysis demonstrated better prognosis when NLR was lower than the cut-off value (P\<0.001; [Fig. S1A](#SD1-ol-0-0-10809){ref-type="supplementary-material"}). Furthermore, PLR had no significant effects on the prognosis (P\>0.05; [Fig. S1B](#SD1-ol-0-0-10809){ref-type="supplementary-material"}). In contrast, LMR higher than the cut-off value predicted poor prognosis (P\<0.001; [Fig. S1C](#SD1-ol-0-0-10809){ref-type="supplementary-material"}).

Discussion
==========

The aim of the present study was to identify simply obtained and inexpensive prognostic factors for PDAC. The prognostic significance of the peripheral blood NLR, PLR and LMR at diagnosis and their association with S100A4 expression in patients with PDAC were investigated. A number of studies have assessed the role of NLR in the outcome of PDAC and suggested that NLR may offer important prognostic information for the survival rate in patients with resectable PDAC ([@b6-ol-0-0-10809],[@b25-ol-0-0-10809]). In the present study, the prognostic role that NLR and LMR serve in PDAC was elucidated. Similarly to previous studies, a high NLR was an independent prognostic marker for the OS of patients with PDAC ([@b6-ol-0-0-10809],[@b14-ol-0-0-10809],[@b26-ol-0-0-10809]). LMR has also been suggested to serve as a simple index of the immune function, and low LMR has been regarded as an independent predictor of poor prognosis in PDAC in a previous study ([@b15-ol-0-0-10809]). Consistent with the results of the previous study, the present study demonstrated that LMR possessed important prognostic information for PDAC and was associated with poor OS. According to studies by Kakkat *et al* ([@b27-ol-0-0-10809]) and Asari *et al* ([@b28-ol-0-0-10809]), high pre-treatment PLR is an independent predictive risk factor for patients with PDAC, which was not demonstrated in the present study. In addition, the majority of the patients received chemotherapy, but the effect of chemotherapy on overall survival was not investigated; the effect of chemotherapy on the statistical importance of NLR and PLR in OS needs to be further explored in the future.

S100A4 is involved in the proliferation, angiogenesis and invasion of tumor cells ([@b29-ol-0-0-10809],[@b30-ol-0-0-10809]). In the present study, it was revealed that patients with high S100A4 tissue expression exhibited unfavorable OS outcomes, which was similar to the results from previous studies ([@b29-ol-0-0-10809]--[@b31-ol-0-0-10809]). However, to the best of our knowledge, there are currently no studies that have been performed with the aim of evaluating the association between peripheral blood NLR, PLR and LMR and S100A4 expression. In the present study, NLR and PLR were positively associated with S100A4 expression, whereas LMR was negatively associated with S100A4 expression. The tumor microenvironment, comprising multiple cellular and molecular factors, serves a pivotal role in the biological behavior of numerous different types of cancer, including PDAC ([@b1-ol-0-0-10809],[@b32-ol-0-0-10809]). The microenvironment surrounding the tumor cells, containing cells of the immune system, is a prerequisite for regulating the initiation of metastasis and affects the prognosis of the malignancy ([@b32-ol-0-0-10809],[@b33-ol-0-0-10809]). The mechanism by which the microenvironment influences tumor metastasis is currently unknown, although it has been suggested to be caused by S100A4 promoting tumor progression, metastasis and inflammation, either systemically or in the tumor microenvironment ([@b34-ol-0-0-10809]).

Certain studies focused on the genetic characteristics of the tumor ([@b35-ol-0-0-10809],[@b36-ol-0-0-10809]). However, a limited number of these prognostic models consider the role of host immunity (i.e., lymphocytes) and the microenvironment produced by the tumor (i.e., monocytes, neutrophils and S100A4) ([@b15-ol-0-0-10809]). In the present study, as well as NLR, peripheral blood LMR was revealed to serve a prognostic role in patients with PDAC. In addition, the association between peripheral blood NLR, PLR and LMR and the tissue expression of S100A4 was thoroughly analyzed in sufficient sample size. However, there were limitations to the present study, including the retrospective design, short follow-up periods and a relatively small sample size.

The present study provided evidence to support the prognostic use of NLR and LMR in patients with PDAC and demonstrated the prognostic relevance of host immunity and tumor-associated microenvironment when determining the clinical outcome. Further studies, including prospective clinical trials and mechanistic studies, are required in order to confirm the conclusions of the present study and reveal the underlying molecular mechanisms.

In conclusion, the present study demonstrated that in the peripheral blood from patients with PDAC, the highest NLR quartile and the lowest LMR quartile were associated with an unfavorable prognosis. The results of the present study also support the prognostic relevance of host immunity and the tumor-associated microenvironment when determining the clinical outcomes of patients with PDAC. As a simply obtained and widely available index at diagnosis, NLR and LMR may be a valid novel predictive and stratification marker for PDAC in clinical practice.
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###### 

Clinicopathological characteristics and treatment modalities in patients with pancreatic ductal adenocarcinoma.

  Characteristic               Number of patients   Percentage
  ---------------------------- -------------------- ------------
  Sex                                               
    Male                       146                  56.6
    Female                     112                  43.4
  T stage at diagnosis                              
    T1                         1                    0.4
    T2                         42                   16.3
    T3                         118                  45.7
    T4                         97                   37.6
  N stage at diagnosis                              
    N0                         111                  43.0
    N1                         119                  46.1
    N2                         28                   10.9
  M stage at diagnosis                              
    M0                         165                  64.0
    M1                         93                   36.0
  Stage at diagnosis                                
    I                          16                   6.2
    II                         24                   9.3
    III                        125                  48.5
    IV                         93                   36.0
  Tumor differentiation                             
    High                       26                   10.1
    Moderate                   109                  42.2
    Poor                       123                  47.7
  Tumor location                                    
    Head and neck              165                  64.0
    Body and tail              93                   36.0
  Adjuvant radiation therapy                        
    Yes                        17                   6.6
    No                         241                  93.4
  Adjuvant chemotherapy                             
    Yes                        219                  84.9
    No                         39                   15.1
  Complications                                     
    Yes                        20                   7.8
    No                         238                  92.2

###### 

Baseline characteristics of patients with pancreatic ductal adenocarcinoma by neutrophil-to-lymphocyte ratio quartiles.

  Variable                     N     1st quartile   2nd quartile   3rd quartile   4th quartile   P-value
  ---------------------------- ----- -------------- -------------- -------------- -------------- -----------------------------------------------------
  Sex                                                                                            0.008^[a](#tfn1-ol-0-0-10809){ref-type="table-fn"}^
    Male                       146   25             39             44             38             
    Female                     112   39             26             21             26             
  T stage at diagnosis                                                                           0.816
    T1+T2                      43    10             10             8              15             
    T3                         118   25             33             32             28             
    T4                         97    26             27             24             20             
  N stage at diagnosis                                                                           0.450
    N0                         111   30             30             30             21             
    N1                         119   31             28             27             33             
    N2                         28    8              7              6              7              
  M stage at diagnosis                                                                           0.116
    M0                         165   45             44             43             33             
    M1                         93    19             21             22             31             
  Stage at diagnosis                                                                             0.617
    I                          16    4              3              4              5              
    II                         24    7              6              6              5              
    III                        125   34             28             36             27             
    IV                         93    19             19             23             23             
  Tumor differentiation                                                                          0.212
    High                       26    12             6              4              4              
    Moderate                   109   25             30             26             28             
    Poor                       123   27             29             35             32             
  Tumor location                                                                                 0.007^[a](#tfn1-ol-0-0-10809){ref-type="table-fn"}^
    Head and neck              165   32             39             51             43             
    Body and tail              93    32             26             14             21             
  Adjuvant radiation therapy                                                                     0.741
    No                         241   60             61             62             58             
    Yes                        17    4              4              3              6              
  Surgery                                                                                        0.833
    None                       105   25             24             27             29             
    Radical                    83    24             20             19             20             
    Palliative                 70    15             21             19             15             
  Adjuvant chemotherapy                                                                          0.906
    None                       39    9              8              12             10             
    GEM                        144   34             36             37             37             
    GEM + others               75    21             21             16             17             
  Complications                                                                                  0.735
    No                         238   61             59             60             58             
    Yes                        20    3              6              5              6              
  CA19-9, U/ml                                                                                   0.037^[a](#tfn1-ol-0-0-10809){ref-type="table-fn"}^
    \<73.68                    64    16             20             12             16             
    73.68--260.45              65    24             18             16             7              
    \>260.45 to ≤1,357         65    12             15             19             19             
    \>1,357                    64    12             12             18             22             

P\<0.05. CA19-9, carbohydrate antigen 19-9; GEM, gemcitabine.

###### 

Baseline characteristics of patients with pancreatic ductal adenocarcinoma by platelet-to-lymphocyte ratio quartiles.

  Variable                     N     1st quartile   2nd quartile   3rd quartile   4th quartile   P-value
  ---------------------------- ----- -------------- -------------- -------------- -------------- -----------------------------------------------------
  Sex                                                                                            0.318
    Male                       146   38             42             34             32             
    Female                     112   26             23             31             32             
  T stage at diagnosis                                                                           0.764
    T1+T2                      43    10             10             10             13             
    T3                         118   27             28             33             30             
    T4                         97    26             30             21             20             
  N stage at diagnosis                                                                           0.803
    N0                         111   27             28             27             29             
    N1                         119   30             29             35             25             
    N2                         28    7              6              9              8              
  M stage at diagnosis                                                                           0.381
    M0                         165   41             38             47             39             
    M1                         93    23             27             18             25             
  Stage at diagnosis                                                                             0.534
    I                          16    5              4              4              3              
    II                         24    7              7              6              4              
    III                        125   32             30             29             34             
    IV                         93    23             26             18             26             
  Tumor differentiation                                                                          0.456
    High                       26    7              3              9              7              
    Moderate                   109   26             33             22             28             
    Poor                       123   31             29             34             29             
  Tumor location                                                                                 0.007^[a](#tfn2-ol-0-0-10809){ref-type="table-fn"}^
    Head and neck              165   32             39             51             43             
    Body and tail              93    32             26             14             21             
  Adjuvant radiation therapy                                                                     0.048^[a](#tfn2-ol-0-0-10809){ref-type="table-fn"}^
    No                         241   57             64             63             57             
    Yes                        17    7              1              2              7              
  Surgery                                                                                        0.457
    None                       105   32             25             23             25             
    Radical                    83    17             21             20             25             
    Palliative                 70    15             19             22             14             
  Adjuvant chemotherapy                                                                          0.173
    None                       39    12             8              9              10             
    GEM                        144   31             33             45             35             
    GEM + others               75    21             24             11             19             
  Complications                                                                                  0.940
    No                         238   60             59             60             59             
    Yes                        20    4              6              5              5              
  CA19-9, U/ml                                                                                   0.118
    \<73.68                    64    14             18             14             18             
    73.68--260.45              65    15             16             23             11             
    \>260.45 to ≤1,357         65    19             9              16             21             
    \>1,357                    64    16             22             12             14             

P\<0.05. CA19-9, carbohydrate antigen 19-9; GEM, gemcitabine.

###### 

Baseline characteristics of patients with pancreatic ductal adenocarcinoma by lymphocyte-to-monocyte ratio quartiles.

  Variable                     N     1st quartile   2nd quartile   3rd quartile   4th quartile   P-value
  ---------------------------- ----- -------------- -------------- -------------- -------------- -----------------------------------------------------
  Sex                                                                                            
    Male                       146   34             47             40             25             0.001^[a](#tfn3-ol-0-0-10809){ref-type="table-fn"}^
    Female                     112   30             18             25             39             
  T stage at diagnosis                                                                           
    T1+T2                      43    11             8              14             10             0.469
    T3                         118   33             28             29             28             
    T4                         97    20             29             26             22             
  N stage at diagnosis                                                                           
    N0                         111   25             31             28             27             0.672
    N1                         119   26             34             32             27             
    N2                         28    6              7              5              10             
  M stage at diagnosis                                                                           
    M0                         165   32             44             44             45             0.062
    M1                         93    32             21             21             19             
  Stage at diagnosis                                                                             
    I                          16    4              3              6              3              0.347
    II                         24    6              5              7              6              
    III                        125   27             32             29             27             
    IV                         93    24             16             29             24             
  Tumor differentiation                                                                          
    High                       26    3              6              6              11             0.225
    Moderate                   109   26             29             32             22             
    Poor                       123   35             30             27             31             
  Tumor location                                                                                 
    Head and neck              165   41             45             37             42             0.521
    Body and tail              93    23             20             28             22             
  Adjuvant radiation therapy                                                                     
    No                         241   60             62             61             58             0.741
    Yes                        17    4              3              4              6              
  Surgery                                                                                        
    None                       105   28             25             24             28             0.906
    Radical                    83    20             19             24             20             
    Palliative                 70    16             21             17             16             
  Adjuvant chemotherapy                                                                          
    None                       39    12             10             10             7              0.852
    GEM                        144   35             33             37             39             
    GEM + others               75    17             22             18             18             
  Complications                                                                                  
    No                         238   57             61             60             60             0.719
    Yes                        20    7              4              5              4              
  CA19-9, U/ml                                                                                   
    \<73.68                    64    17             15             18             14             0.228
    73.68--260.45              65    7              18             20             20             
    \>260.45 to ≤1,357         65    19             15             16             15             
    \>1,357                    64    21             17             11             15             

P\<0.05. CA19-9, carbohydrate antigen 19-9; GEM, gemcitabine.

###### 

Hazard ratios of baseline characteristics for mortality in patients with pancreatic ductal adenocarcinoma.

  Variable                            Hazard ratio (95% CI)   P-value
  ----------------------------------- ----------------------- -------------------------------------------------------
  Sex                                 0.877 (0.650--1.182)    0.388
  Age                                 1.108 (1.002--1.035)    0.026^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
  Stage at diagnosis (ref: I)                                 \<0.00^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    II                                0.431 (0.219--0.969)    1.512
    III                               4.652 (1.773--8.437)    \<0.001^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    IV                                3.273 (1.728--6.202)    \<0.001^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
  Tumor differentiation (ref: High)                           \<0.001^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    Moderate                          2.898 (1.538--5.459)    0.001^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    Poor                              5.524 (2.900--10.522)   \<0.001^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
  Tumor location                      1.140 (0.839--1.551)    0.402
  Radiation therapy                   0.934 (0.531--1.645)    0.814
  Complications                       0.737 (0.426--1.275)    0.275
  Surgery (ref: None)                                         \<0.001^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    Radical                           0.372 (0.257--0.539)    \<0.001^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    Palliative                        0.688 (0.483--0.979)    0.038^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
  Chemotherapy (ref: None)                                    0.037^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    GEM                               0.628 (0.421--0.939)    0.023 ^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    GEM + others                      0.579 (0.371--0.901)    0.016^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
  CA19-9 (ref: ≤73.68)                                        0.004^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    \>73.68 to 260.45                 1.367 (0.881--2.121)    0.164
    \>260.45 to ≤1357                 1.494 (0.970--2.300)    0.068
    \>1357                            2.163 (1.419--3.297)    \<0.001^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
  NLR quartile (ref: 1st)                                     0.009^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    2nd                               0.945 (0.612--1.459)    0.797
    3rd                               1.414 (0.925--2.161)    0.109
    4th                               1.765 (1.164--2.676)    0.007^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
  PLR quartile (ref: 1st)                                     0.767
    2nd                               0.927 (0.608--1.414)    0.725
    3rd                               1.045 (0.687--1.588)    0.838
    4th                               1.156 (0.762--1.753)    0.495
  LMR quartile (ref: 1st)                                     0.007^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    2nd                               0.763 (0.513--1.133)    0.179
    3rd                               0.586 (0.387--0.886)    0.011^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^
    4th                               0.501 (0.328--0.765)    0.001^[a](#tfn4-ol-0-0-10809){ref-type="table-fn"}^

P\<0.05. Ref, reference; GEM, gemcitabine; CA19-9, carbohydrate antigen 19-9; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.

###### 

Cox proportional multivariate hazard models in patients with pancreatic ductal adenocarcinoma.

  A, Model A1 (NLR as a continuous variable)                                    
  ------------------------------------------------- --------------------------- -------------------------------------------------------
  NLR                                               1.198 (1.033--1.389)        0.017^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
  Age                                               1.014 (0.996--1.032)        0.133
  Stage at diagnosis (ref: I)                                                   0.012^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    II                                              1.199 (0.583--2.465)        0.622
    III                                             2.968 (1.382--6.056)        0.004^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    IV                                              2.366 (1.047--5.345)        0.038^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
  Tumor differentiation (ref: High)                                             \<0.001^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    Moderate                                        2.248 (1.175--4.299)        0.014^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    Poor                                            3.942 (2.004--7.752)        \<0.001^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
  Surgery (ref: None)                                                           \<0.001^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    Radical                                         0.578 (0.335--0.997)        0.049^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    Palliative                                      0.874 (0.595--1.285)        0.495
  Chemotherapy (ref: None)                                                      0.037^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    GEM                                             0.682 (0.433--1.073)        0.098
    GEM + others                                    0.650 (0.402--1.052)        0.080
  CA19-9 (ref: ≤73.68)                                                          0.004^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    \>73.68 to 260.45                               1.373 (0.849--2.221)        0.197
    \>260.45 to ≤1357                               1.249 (0.802--1.944)        0.326
    \>1357                                          1.503 (0.967--2.337)        0.070
                                                                                
  **B, Model B1 (LMR as a continuous variable)**                                
                                                                                
  **Variable**                                      **Hazard ratio (95% CI)**   **P-value**
                                                                                
  LMR                                               0.846 (0.734--0.975)        0.021^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
  Age                                               1.012 (0.994--1.031)        0.181
  Stage at diagnosis (ref: I)                                                   0.012^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    II                                              1.169 (0.570--2.399)        0.669
    III                                             2.786 (1.438--5.894)        0.010^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    IV                                              2.214 (0.985--4.975)        0.054
  Tumor differentiation                                                         \<0.001^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
  (ref: High)                                                                   
    Moderate                                        2.215 (1.160--4.232)        0.016^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    Poor                                            3.861 (1.964--7.589)        \<0.001^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
  Surgery (ref: None)                                                           \<0.001^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    Radical                                         0.566 (0.329--0.973)        0.040^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    Palliative                                      0.855 (0.581--1.260)        0.429
  Chemotherapy (ref: None)                                                      0.037^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    GEM                                             0.693 (0.441--1.090)        0.113
    GEM + others                                    0.638 (0.394--1.034)        0.068
  CA19-9, U/ml (ref: ≤73.68)                                                    0.004^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    \>73.68 to 260.45                               1.345 (0.833--2.174)        0.226
    \>260.45 to ≤1,357                              1.272 (0.815--1.985)        0.289
    \>1,357                                         1.504 (0.965--2.345)        0.071
                                                                                
  **C, Model A2 (NLR as a categorical variable)**                               
                                                                                
  **Variable**                                      **Hazard ratio (95% CI)**   **P-value**
                                                                                
  NLR quartile (ref: 1st)                                                         0.019^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    2nd                                             0.769 (0.487--1.214)        0.259
    3rd                                             1.124 (0.725--1.743)        0.602
    4th                                             1.543 (0.986--2.415)        0.058
                                                                                
  **D, Model B2 (LMR as a categorical variable)**                               
                                                                                
  **Variable**                                      **Hazard ratio (95% CI)**   **P-value**
                                                                                
  LMR quartile (ref: 1st)                                                       0.088
    2nd                                             0.952 (0.621--1.458)        0.820
    3rd                                             0.642 (0.414--0.996)          0.048^[a](#tfn5-ol-0-0-10809){ref-type="table-fn"}^
    4th                                             0.663 (0.422--1.040)        0.074

P\<0.05. Ref, reference; GEM, gemcitabine; CA19-9, carbohydrate antigen 19-9; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.

[^1]: Contributed equally
